Delivery Order SPE2DX15D2012-SPE2DX22F7UB1
Award Date 1/21/22
Potential Completion Date 1/24/22
Potential Value $4.2K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distributor. The contract has a ceiling value of $8,239.50 and an ultimate completion date of October 25, 2023. It is a delivery order contract with a firm fixed price pricing type. The contract...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA), a Department of Defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, under a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that runs through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA) Troop Support Medical. The $2,446.44 fixed-price delivery order was issued to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 22, 2022 and does not utilize any set-aside designations. Amerisourcebergen Drug Corp, a subsidiary of the parent company...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a prescription eye medication, to the Defense Logistics Agency (DLA). The $1,890.84 firm fixed-price delivery order was awarded to prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract has a ceiling value of $12,517.29 and is a firm fixed-price delivery order with a completion date of May 16, 2023. The contract is part of a larger Indefinite Delivery...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The contract, valued at $43,718.11, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a firm fixed-price delivery order with an ultimate completion date of December 7, 2023. The award is not designated with a set-aside and appears to be made through full and open competition. Amerisourcebergen...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,676.81, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract has a period of performance that runs through February 29, 2024 and is structured as a firm fixed-price delivery order. No set-aside designation was used for this award. Amerisourcebergen Drug...
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The contract, valued at $4,986.02, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued up to $999,999,999.00, serves as the...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a ceiling value of $1,372.38. The contract is a Firm Fixed Price Delivery Order with a performance period ending on June 27, 2025. It is not designated as a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The fixed-price delivery order, valued at $4,356.93, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 23, 2024 and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...